tiprankstipranks
Trending News
More News >
Dyne Therapeutics (DYN)
NASDAQ:DYN
US Market

Dyne Therapeutics (DYN) AI Stock Analysis

Compare
334 Followers

Top Page

DY

Dyne Therapeutics

(NASDAQ:DYN)

Rating:43Neutral
Price Target:
Dyne Therapeutics' stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.
Positive Factors
Clinical Development
DYNE-101 delivers consistent/sustained treatment benefit at 12mo, showing improvement in myotonia, muscle strength, mobility, and patient-reported outcomes, with consistent safety.
Competitive Positioning
VHOT strengthens DYNE-101's competitive positioning—competitor might be powered for multiple endpoints.
Regulatory Approval
Dyne announced FDA Breakthrough Therapy Designation and updated plan for accelerated approval in myotonic dystrophy type 1.
Negative Factors
Investor Sentiment
The primary endpoint change to vHOT from CASI-22 could trigger some investor questions or concerns.
Investor Skepticism
The change from splicing to vHOT represents a significant shift that may cause confusion and skepticism among investors.

Dyne Therapeutics (DYN) vs. SPDR S&P 500 ETF (SPY)

Dyne Therapeutics Business Overview & Revenue Model

Company DescriptionDyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
How the Company Makes MoneyDyne Therapeutics generates revenue primarily through strategic collaborations, partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments for achieving specific clinical or regulatory goals, and royalties on sales of any successfully commercialized products. Additionally, Dyne may receive funding through research grants and government contracts aimed at advancing its therapeutic programs. As the company progresses towards commercialization, potential revenue streams could also include direct sales of approved therapies or sublicensing opportunities with other entities.

Dyne Therapeutics Financial Statement Overview

Summary
Dyne Therapeutics exhibits characteristics typical of an early-stage biotech firm: significant cash reserves and low leverage support its R&D focus, despite zero revenue and increasing net losses. The strong balance sheet mitigates the risks associated with negative cash flows, contingent on future breakthroughs and commercialization.
Income Statement
15
Very Negative
Dyne Therapeutics has consistently reported zero revenue over the years, reflecting its early-stage position in the biotechnology sector focused on R&D. The company incurs substantial net losses, which have been increasing over time, indicating high operational expenses without offsetting revenue streams. This results in negative profit margins across all metrics, which is typical for a biotech firm in the pre-commercial phase.
Balance Sheet
70
Positive
The balance sheet is relatively strong with a significant amount of cash and short-term investments, which is crucial for sustaining R&D activities. The company maintains low debt levels relative to its equity, reflected in a healthy debt-to-equity ratio. A robust equity ratio indicates a strong capital structure, providing financial stability and reducing immediate liquidity risks.
Cash Flow
40
Negative
Cash flows are deeply negative, driven by heavy R&D investments, a common scenario for pre-revenue biotech companies. However, the substantial cash on hand and positive financing cash flow from equity funding highlight the company's ability to raise capital, enabling it to continue its development projects despite negative free cash flow growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-400.00K0.00-2.46M-3.35M-1.09M-700.00K
EBITDA-395.71M-315.18M-233.48M-164.75M-148.20M-58.34M
Net Income-367.13M-317.42M-235.94M-165.24M-149.28M-58.74M
Balance Sheet
Total Assets721.07M691.23M165.08M306.32M425.66M353.33M
Cash, Cash Equivalents and Short-Term Investments677.49M642.27M123.10M256.01M376.57M345.31M
Total Debt23.33M23.99M27.41M30.48M32.64M0.00
Total Liabilities52.10M61.40M73.79M53.96M57.47M10.97M
Stockholders Equity668.97M629.84M91.29M252.36M368.20M342.37M
Cash Flow
Free Cash Flow-322.89M-294.75M-188.89M-156.71M-123.18M-47.67M
Operating Cash Flow-319.73M-292.37M-188.16M-153.65M-119.56M-46.51M
Investing Cash Flow-22.78M-204.08M83.31M87.20M-137.89M-45.66M
Financing Cash Flow542.75M809.89M54.32M37.39M157.82M380.69M

Dyne Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price8.68
Price Trends
50DMA
11.74
Negative
100DMA
11.60
Negative
200DMA
19.35
Negative
Market Momentum
MACD
-0.87
Positive
RSI
30.78
Neutral
STOCH
10.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Negative. The current price of 8.68 is below the 20-day moving average (MA) of 11.92, below the 50-day MA of 11.74, and below the 200-day MA of 19.35, indicating a bearish trend. The MACD of -0.87 indicates Positive momentum. The RSI at 30.78 is Neutral, neither overbought nor oversold. The STOCH value of 10.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYN.

Dyne Therapeutics Risk Analysis

Dyne Therapeutics disclosed 80 risk factors in its most recent earnings report. Dyne Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Dyne Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$1.18B-49.41%4.86%10.13%
WVWVE
50
Neutral
$1.01B-105.50%-7.06%-57.17%
48
Neutral
$758.94M-93.70%-25.83%
48
Neutral
$581.05M-51.85%11070.12%32.07%
46
Neutral
C$192.85M-4.25-8.56%2.91%13.52%-1.74%
DYDYN
43
Neutral
$986.63M-64.01%14.93%
36
Underperform
$1.16B-31.30%12.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DYN
Dyne Therapeutics
8.94
-25.46
-74.01%
IOVA
Iovance Biotherapeutics
1.75
-5.53
-75.96%
VRDN
Viridian Therapeutics
14.47
2.15
17.45%
WVE
Wave Life Sciences
6.75
1.28
23.40%
SNDX
Syndax Pharmaceuticals
8.82
-12.11
-57.86%
ELVN
Enliven Therapeutics
19.65
-2.77
-12.36%

Dyne Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Dyne Therapeutics Appoints Erick Lucera as CFO
Positive
Mar 20, 2025

On March 20, 2025, Dyne Therapeutics announced the appointment of Erick Lucera as Chief Financial Officer and Treasurer, effective March 31, 2025. This strategic move follows Lucera’s extensive experience in financial leadership roles within the biotechnology sector, notably at Editas Medicine and AVEO Pharmaceuticals. His appointment coincides with the departure of Richard Scalzo, who will transition to a consulting role. These changes are expected to enhance Dyne Therapeutics’ financial strategy and operational efficiency, potentially impacting its market positioning positively.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2025